Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Synaptosomal-associated protein 25 kDa (SNAP-25) and Synaptobrevin (VAMP1 or VAMP2) (SNAP-25; VAMP1, VAMP2)
- Target
- SNAP-25; VAMP1, VAMP2
- Molecular classification
- SNARE protein, membrane trafficking protein, exocytosis machinery, vesicle-associated membrane protein
01
Overview
SNAP-25 (Synaptosomal-associated protein 25 kDa) and synaptobrevin (VAMP1/VAMP2) are core components of the SNARE complex, a molecular machine essential for calcium-triggered synaptic vesicle fusion and neurotransmitter release at the neuromuscular junction and cholinergic nerve terminals[2][3][4][5][6]. Cleavage of either protein by specific neurotoxins (notably botulinum and tetanus toxins) prevents SNARE complex assembly, thereby abolishing acetylcholine exocytosis and inducing rapid, profound paralysis. These proteins are integral to normal synaptic transmission, and their disruption underlies the mechanism of action for various neurotoxins and therapeutic agents targeting neurotransmitter release.
- Other names
- Synaptosomal-associated protein 25t-SNARE proteinVAMP1 (synaptobrevin-1)VAMP2 (synaptobrevin-2)v-SNARE protein
02
Mechanism of action
Proteolytic cleavage of SNAP-25 or synaptobrevin by neurotoxins prevents SNARE complex formation, thereby blocking acetylcholine vesicle exocytosis and neurotransmitter release, causing synaptic failure and paralysis
03
Biological functions
Synaptic vesicle fusion (exocytosis) at presynaptic terminalNeurotransmitter release (acetylcholine and others)Synaptic plasticity and regulation of synaptic efficacy
04
Disease associations
Botulism (toxin-induced paralysis)Neurodevelopmental disorders, psychiatric and neurological diseases associated with SNARE dysfunctionMotor disorders, neuromuscular defects
05
Safety considerations
Complete inhibition causes flaccid paralysis and life-threatening respiratory failure (botulism)Off-target effects and systemic toxicity are concerns in toxin-based therapies
06
Interacting drugs
Botulinum neurotoxins (types A, B, C, E, F)
1 more in the full profile.
07
Biomarkers
Reduced or cleaved SNAP-25 or synaptobrevin in patient samples for toxin exposureParalysis or decrement of compound muscle action potential (CMAP) for functional monitoring
Beyond the preview
Go deeper on Synaptosomal-associated protein 25 kDa (SNAP-25) and Synaptobrevin (VAMP1 or VAMP2) (SNAP-25; VAMP1, VAMP2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synaptosomal-associated protein 25 kDa (SNAP-25) and Synaptobrevin (VAMP1 or VAMP2) (SNAP-25; VAMP1, VAMP2).